Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy
Information source: M.D. Anderson Cancer Center
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Prostate Cancer
Intervention: LHRH Agonist (Drug); Sunitinib Malate (Drug); Radical Prostatectomy (Procedure)
Phase: Phase 2
Sponsored by: M.D. Anderson Cancer Center
Official(s) and/or principal investigator(s):
Amado Zurita, MD, Principal Investigator, Affiliation: U.T.M.D. Anderson Cancer Center
Cherie A Perez, BS, Phone: 713-563-1602
1. To evaluate the pathological complete response (pCR) rate to neoadjuvant hormonal
ablation and SU011248/sunitinib malate in high-risk localized prostate cancer.
1. To evaluate the time to PSA-progression after neoadjuvant hormonal ablation and
SU011248/sunitinib malate, and Radical Prostatectomy (RP), in high-risk localized
2. To evaluate the perioperative and postoperative morbidity with RP after neoadjuvant
hormonal ablation and SU011248/sunitinib malate.
3. To identify and measure molecular biomarkers for neoadjuvant hormonal ablation and
SU011248/sunitinib malate (optional studies).
Official title: A Phase II Neoadjuvant Trial of Sunitinib Malate (SU011248) Plus Hormonal Ablation for Patients Who Have High Risk Localized Prostate Cancer and Will Undergo Prostatectomy
Study design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Primary outcome: Number of Participants With Pathological Complete Response (pCR)
Sunitinib malate is designed to block pathways that control important events such as the
growth of blood vessels that are essential for the growth of cancer. Hormonal treatment is
used to lower testosterone levels in the body because prostate cancer cells need
testosterone to survive.
Before you can start treatment on this study, you will have what are called "screening
tests." These tests will help the doctor decide if you are eligible to take part in this
study. Your complete medical history will be recorded. You will have a physical exam,
including measurement of vital signs (blood pressure, pulse, temperature, and weight).
Blood (about 2 teaspoons) and urine will be collected for routine tests. You will have a
computerized tomography (CT) or magnetic resonance imaging (MRI) scan, a bone scan, or a
chest x-ray to evaluate the status of your disease. You will be asked about any medications
or treatments you are currently taking. You will have an electrocardiogram (ECG - a test
that measures the electrical activity of the heart) and an echocardiogram. An echocardiogram
uses sound waves to make pictures of your heart, which helps show how well your heart pumps
blood. You will be asked to lie on your left side while a technician places a probe with
gel on your chest to create images of your heart to determine the function and size. Your
ability to perform daily activities will also be evaluated. You will have a bone marrow
aspirate and biopsy. To collect a bone marrow aspirate and biopsy, an area of the hip or
chest bone is numbed with anesthetic, and a small amount of bone marrow and bone is
withdrawn through a large needle.
If you are found to be eligible to take part in this study, you will take the sunitinib
malate by mouth 1 time a day for 30 days together with hormonal ablation therapy. You will
receive hormone injections to lower the levels of testosterone in the blood. Hormonal
therapy may be given either monthly for 3 months or in a single 3-month dose. Every 30 days
is considered a study "cycle." You may receive up to 3 cycles of treatment.
On Day 1 of each cycle, you will have a physical exam and you will be asked about your
medical history. Blood (about 2 teaspoons) will be drawn for routine tests. You will be
asked about any medications you have taken and any side effects you may have experienced.
You will be asked questions about your ability to perform daily activities (performance
On Day 15 of each cycle, you will be asked about any side effects you have experienced.
Blood (about 2 teaspoons) will be drawn for routine testing.
After completing 3 cycles of treatment, you will have surgery to remove your prostate. The
surgery will occur 1-2 weeks after you receive the last dose of study drug.
After the last dose of the study drug, you will have a follow-up visit. You will be asked
about any side effects you are experiencing and you will have a physical exam. You will
also have digital rectal exam. Blood (about 2 teaspoons) will be drawn for routine tests.
You will also have an echocardiogram. An echocardiogram uses sound waves to make pictures
of your heart, which helps show how well your heart pumps blood. You will be asked to lie
on your left side while a technician places a probe with gel on your chest to create images
of your heart to determine the function and size.
You will have a follow-up visit, 28 days after you stop treatment. You will have a physical
exam and your complete medical history will be recorded. Blood (about 2 teaspoons) will be
drawn for routine tests. You will be asked about any medications you have taken and any
side effects you may have experienced. You will have a performance status evaluation. You
will have an echocardiogram if it was abnormal at your last visit.
About 3 months after your surgery, you will return for another follow-up visit. You will
have a physical exam and your complete medical history will be recorded. Blood (about 2
teaspoons) will be drawn for routine tests. You will have a performance status evaluation.
For the first year after surgery you will have a prostate specific antigen (PSA) blood test
every 3 months. Two (2) years after surgery you will begin having PSA tests every 6 months.
Minimum age: N/A.
Maximum age: N/A.
1. Patients with histologically confirmed adenocarcinoma of the prostate that in the
opinion of the surgeon is resectable. Ductal adenocarcinoma of the prostate is
2. All patients must be regarded as low anesthetic risk for radical prostatectomy and
confirm their intention to undergo radical prostatectomy at the end of the
3. All patients must have one of the following high-risk features: clinical (c) T
(subscript) 3 disease or Gleason 8-10 adenocarcinoma or cT (subscript) 2 (subscript)
b-c and PSA >= 10 ng/ml and Gleason 7 adenocarcinoma. The 1992 AJCC staging system
will be followed.
4. ECOG performance status 0 or 1.
5. Prior hormonal therapy up to 2 months is permitted.
6. Patients must have adequate bone marrow function defined as an absolute peripheral
granulocyte count of >= 1,500/mm^3 and platelet count of >= 100,000/mm^3; hemoglobin
>= 9. 0 g/dl; adequate hepatic function defined as a total bilirubin of <= 1. 5 mg/dl
and AST/ALT <= 2 x the upper limit of normal; adequate renal function defined as
serum creatinine <= 1. 5 x the upper limits of normal or creatinine clearance >= 40
cc/min (measured or calculated).
7. Patients must sign the current IRB approved informed consent indicating that they are
aware of the investigational nature of this study, in keeping with the policies of
8. All patients must have a surgical and medical oncology consult prior to signing
1. Patients with small cell or sarcomatoid prostate cancers are not eligible.
2. Patients with clinical or radiological evidence of metastatic disease.
3. Patients receiving ketoconazole as a prior hormonal therapy.
4. Prior chemotherapy or experimental agents for prostate cancer.
5. Patients with any infection process, in the criterion of the investigator, that could
worsen or its outcome be affected, as a result of the investigational therapy.
6. Patients with NYHA Class III/IV congestive heart failure, unstable angina,
cerebrovascular accident or transient ischemic attack, or pulmonary embolism or
myocardial infarction in the last 6 months.
7. Uncontrolled severe hypertension ( >= 140/90 despite controlling medication),
uncontrolled diabetes mellitus, oxygen-dependent lung disease, known chronic liver
disease or HIV infection.
8. Second malignancies (excluding non-melanoma skin cancer) unless disease-free for 3
9. Ongoing treatment with therapeutic doses of coumadin. However, low dose coumadin up
to 2 mg PO daily for deep vein thrombosis prophylaxis is allowed. Low molecular
weight heparin is allowed.
10. Overt psychosis, mental disability or otherwise incompetent to give informed consent
or history of non-compliance.
Locations and Contacts
Cherie A Perez, BS, Phone: 713-563-1602
U.T.M.D. Anderson Cancer Center, Houston, Texas 77030, United States; Recruiting
Amado Zurita, MD, Principal Investigator
UT MD Anderson Cancer Center
Starting date: May 2006
Ending date: December 2012
Last updated: August 28, 2009